‘Real Housewives’ star talks about life after losing 30 pounds by using a GLP-1
“Real Housewives of New Jersey” star Dolores Catania candidly shared her experience with taking weight loss medication and how her life – and diet – have changed since her dramatic weight loss. Subscribe to ABC News on YouTube: https://abcnews.visitlink.me/59aJ1G ABC News Digital is your daily source of breaking national and world news, exclusive interviews and […]
Better Limb Protection With Semaglutide vs Common T2D Meds
Among patients with type 2 diabetes and peripheral artery disease or foot ulcers, the use of semaglutide is linked to a markedly lower risk for major limb events than the use of other glucose-lowering drugs. Medscape Medical News
Which factors affect the success of popular prescription weight loss drugs in individuals?
A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people’s weight loss after taking prescription drugs called glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide (sold under the brand names Ozempic and Wegovy).
Seeking strategic business partners for weight loss peptides and GLP-1
I am looking for a strategic partner for slimming peptides. Requirements: 1. People who have used slimming peptides or GLP-1 products. 2. Have a certain understanding and knowledge of these products. 3… (Budget: $24000 – $40000 HKD, Jobs: Affiliate Marketing, Brand Management, Business Consulting, Business Development, Facebook Marketing, Health, Marketing, Sales, Social Media Marketing, Social […]
Glucagon‐like peptide‐1 receptor agonist treatment associated weight fluctuation and influencing factors in patients with overweight or obesity
Abstract Objective To characterize the weight fluctuation and explore its influencing factors after glucagon-like peptide 1 receptor agonist (GLP-1RA) treatment in patients with overweight or obesity. Methods This retrospective cohort study enrolled 679 patients with overweight or obesity who initiated GLP-1RA treatment between November 2022 and October 2024. The weight measurements were collected during in-person […]
Altimmune (ALT) Reports Positive Phase 2b Results for Pemvidutide in MASH Trial
Altimmune, Inc. (NASDAQ:ALT) is one of Goldman Sachs’ top penny stock picks. On June 26, the company reported positive topline results from its Phase 2b IMPACT trial evaluating Pemvidutide, a treatment candidate for metabolic dysfunction-associated steatohepatitis (MASH). The results mark a key milestone in advancing potential therapies for this chronic liver condition. A biotechnologist in […]
CVS Caremark drops coverage of popular weight loss drug
CVS Caremark, one of the three major pharmacy benefit managers (PBM) in the U.S., stopped coverage for Eli Lilly’s popular weight-loss drug Zepbound, blaming drugs like it for driving up overall plan costs. GLP-1 products, originally developed to treat type 2 diabetes, but are now FDA-approved specifically for obesity under brand names like Wegovy and […]
Formerly bankrupt weight loss company makes a comeback
When it comes to things that most concern Americans about their health, weight loss is often at the top of the list. While America doesn’t have the top obesity rate in the world, it does rank high on the list. More than 45% of Americans are obese. But the issue is bigger than just in […]
Eat more steak if you are taking anti-fat drugs
Red meat is full of collagen but not a great option for vegans Losing weight is a struggle and a reason to stay alive. Being obese comes with all sorts of health consequences and if you can’t manage it with diet and exercise you may be taking an anti-obesity drug. To gain the best effects, […]
Age and Sex Differences in Treatment Efficacy for Type 2 Diabetes
To the Editor A recent network meta-analysis reported that sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists were associated with lower risk of major adverse cardiovascular events and that the 3 newer glucose-lowering agents exhibited no observable interactions with age or sex. Three points merit further consideration.